Difference between revisions of "Trastuzumab-strf (Hercessi)"
(Created page with "'''Note: this is a biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.''' ==General informatio...") |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex") |
||
Line 5: | Line 5: | ||
<br>Extravasation: [[neutral]] | <br>Extravasation: [[neutral]] | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. |
==Diseases for which it is established== | ==Diseases for which it is established== |
Revision as of 01:52, 29 June 2024
Note: this is a biosimilar. The information below is reproduced from the Trastuzumab (Herceptin) page, except for the details of FDA indication.
General information
Class/mechanism: HER2/neu receptor antagonist, humanized IgG1 kappa monoclonal antibody. Trastuzumab binds to the extracellular domain of HER2/erbB2 (human epidermal growth factor receptor 2), which is overexpressed in certain malignancies. Trastuzumab helps to mediate antibody-dependent cellular cytotoxicity (ADCC) preferentially against cells that overexpress HER2.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is established
Patient drug information
To be completed
History of changes in FDA indication
- 2024-04-29: Initial approval for adjuvant treatment of HER2-overexpressing breast cancer.
- 2024-04-29: Initial approval for the treatment of HER2-overexpressing metastatic breast cancer. (Based on HLX02-BC01)
- 2024-04-29: Initial approval for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Also known as
- Code name: HLX-02
- Brand name: Hercessi